ASCO 2021: Nivolumab plus ipilimumab for the treatment of kidney cancer brain metastases

Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are stopped from getting to the brain by a membrane called the blood-brain barrier. Most patients with brain metastases have, therefore, been excluded from phase 3 clinical trials. In the phase 3/4 CheckMate 920 study, presented at […]

read more

ASCO 2021: Baseline characteristics affect survival with nivolumab plus cabozantinib

Ongoing results from the phase 3 CheckMate-9ER clinical trial with nivolumab plus cabozantinib were presented a the American Society for Clinical Oncology (ASCO) Annual Meeting over the weekend. The nivolumab/cabozantinib combination doubled the average time to when the treatment stopped working and the cancer started growing again (progression-free survival) compared to sunitinib and nearly twice […]

read more

ASCO 2021: Nivolumab plus cabozanitinib for non-clear cell kidney cancer

The cabozantinib/nivolumab combination has been shown to be effective at improving survival in patients with metastatic clear cell renal cell carcinoma (RCC) in a phase 3 trial. This poster presentation from the American Society for Clinical Oncology (ASCO) Annual Meeting at the weekend reports the results of a phase 2 trial of cabozantinib/nivolumab in patients […]

read more

ASCO 2021: Telaglenastat plus cabozantinib for metastatic kidney cancer

Cell metabolism in renal cell carcinoma (RCC) tumours is disrupted, and RCC tumour cells tend to have high levels of an enzyme called glutaminase, a key enzyme for the metabolism of glutamine. Glutamine is an amino acid that is found in most proteins. It is a source of energy for cell growth. Telaglenastat is a […]

read more

ASCO 2021: Health-related quality of life for lenvatinib plus pembrolizumab for advanced kidney cancer

Results from the phase 3 CLEAR study were presented at the American Society for Clinical Oncology (ASCO) Annual Meeting at the weekend. Previous studies have shown that lenvatinib (VEGF inhibitor) used together with pembrolizumab (immune checkpoint inhibitor) resulted in better survival and cancer shrinkage compared to sunitinib when used for patients with advanced renal cell […]

read more

ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer

The cabozantinib/nivolumab combination has been shown to be effective at improving survival in patients with metastatic clear cell renal cell carcinoma (RCC) in a phase 3 trial. This study, presented at the American Society for Clinical Oncology (ASCO) Annual Meeting held virtually over the weekend reports the results of a phase 2 trial of cabozantinib/nivolumab […]

read more

ASCO 2021: Pembrolizumab as adjuvant therapy for kidney cancer

Adjuvant therapy is medication that is given in addition to surgery (nephrectomy) to try to prevent the cancer from coming back. Adjuvant therapy can be used to kill any remaining microscopic cancer cells, or it can control the growth of any remaining cancer. Nephrectomy is the standard of care for renal cell carcinoma (RCC); however, […]

read more

ASCO GU 2021: Outcomes of first-line immunotherapy combinations in metastatic kidney cancer

Combinations of immunotherapy drugs nivolumab plus ipilimumab and immunotherapy/vascular endothelial growth factor (VEGF) inhibitors are widely used for the treatment of metastatic renal cell carcinoma (RCC). However, limited information is available to compare the outcomes from different combinations. At the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) over the weekend, data […]

read more

ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer

Results from the phase 3 CLEAR study, presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium over the weekend, showed that lenvatinib used in combination with either pembrolizumab or everolimus resulted in improved survival and tumour shrinkage compared to sunitinib when used as a first-line treatment for patients with advanced renal cell […]

read more

ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer

A gene called MET codes for a protein called MET tyrosine protein kinase (also called hepatocyte growth factor receptor), which¬† stimulates the growth and development of tumours. MET tyrosine protein kinase is a key driver of the growth and development of papillary renal cell carcinoma (pRCC). In this study presented at the American Society of […]

read more
Showing 1 to 10 of 43 results
  TOP